Semaglutide Compounding

Compounding Pharmacy Regulation in Australia: The TGA, GLP-1 Shortages, and the Policy Tension

How TGA Section 19A, compounded semaglutide and tirzepatide during national shortages, the BPC-157 Schedule 4 reclassification, and Pharmacy Board notifications have turned compounding into a national policy issue balancing patient access against sterile-injectable safety.